Novartis

Novartis Joins the Global Chagas Disease Coalition and Also Announces First Multinational, Prospective, Randomized Study in People With Chronic Chagas Cardiomyopathy

Summary: 
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
  • Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
  • Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
  • Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
  • The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5

Novartis Receives FDA Approval for Egaten® for the Treatment of Fascioliasis, a Neglected Tropical Disease

Summary: 
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Press Release
  • Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO

  • Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally1

  • Novartis has been donating Egaten to the WHO since 2005, helping to treat around 2 million patients in more than 30 countries

  • FDA approval reinforces the company’s commitment to reduce the burden of neglected tropical diseases including fascioliasis, leprosy and malaria

Novartis Releases Novartis in Society 2018 Report

Article

For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).

Sandoz Certified Global Top Employer 2019

Summary: 
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy
Press Release
  • Sandoz has been officially certified by the Top Employers Institute for its exceptional employee offerings globally
  • The Top Employers Institute is generally acknowledged as the global authority on recognizing excellence in people practices
  • This exclusive certification underlines our commitment to build a great place to work, based on a strong purpose-driven strategy

Government of Ghana Launches First of Its Kind Public-Private Partnership With Novartis to Improve Diagnosis and Treatment of People With Sickle Cell Disease

Summary: 
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1
Press Release
  • Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
  • Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
  • 15 000 babies are born with sickle cell disease every year in Ghana1

Sandoz Selects Three Finalists for Healthcare Access Challenge (Sandoz HACk) From Over 400 Global Entries

Summary: 
  • Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
  • Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
  • Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging
Press Release
  • Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
  • Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
  • Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging

Join Purpose-Driven Leaders at the 2019 Shared Value Leadership Summit

Registration now open for the premier venue for shared value leaders
Blog

May 7-8, 2019 

Marriott Long Wharf | Boston, Massachusetts

The era of purpose-driven business is upon us: from investors to global brands to consumers and CEOs alike, seemingly everyone is talking about the importance of purpose in driving business strategy and societal well-being. How can organizations fully deliver on the promise of purpose, moving from inspirational vision to meaningful results?​

Novartis Access Launches in Latin America

The program will be implemented in El Salvador through a partnership with the municipality of Santa Tecla and in Colombia through an agreement with the Colombian Red Cross to help migrant populations in the country.
Article

Novartis has signed an agreement with the municipality and the Patronato of Santa Tecla in El Salvador to distribute the Novartis Access portfolio to low-income patients with non-communicable diseases (NCDs) in this community. Beyond medications, the collaboration will also help train health professionals in NCD diagnosis and treatment, and promote education and awareness in the local community.

Novartis Social Business Joins Forces With THET to Train Hospital and Health Center Staff in Ethiopia

This new partnership responds to a request for training and capacity building from the Ethiopian Federal Ministry of Health to support its decentralization strategy for non-communicable disease services.
Article

We are pleased to announce that and The Tropical Health and Education Trust (THET) have come to an agreement to train hospital and health center staff at 60 sites across Ethiopia, ensuring that patients no longer need to travel long distances to seek treatment against non-communicable diseases (NCDs).

When the Shopkeeper Measures Blood Pressure: Novartis Foundation and Partners Prove Effectiveness of Community-based Approach to Tackling Hypertension

Novartis Foundation and partners’ innovative ComHIP pilot in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease.
Summary: 

• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease

• Digital health tools were a key enabler in the program

• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%

• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions

• This form of community-based care could save millions of lives in other countries and for other NCDs

Article

• Innovative ComHIP project in Ghana shows that bringing healthcare closer to where people live, work and shop effectively tackles hypertension – the most deadly non-communicable disease

• Digital health tools were a key enabler in the program

• The control rate of people with hypertension enrolled and retained in the program for over a year climbed from 36% to 72%

• The Ghanaian government is integrating the model into national policy and plans to scale-up to additional regions

• This form of community-based care could save millions of lives in other countries and for other NCDs

Pages

Subscribe to Novartis